Ignite Creation Date:
2024-05-05 @ 10:23 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00005402
Status:
COMPLETED
Last Update Posted:
2015-12-17
First Post:
2000-05-25
Brief Title:
Transfusion Associated HCV in a Pediatric Population
Sponsor:
Naomi Luban
Organization:
Childrens National Research Institute
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2002-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To identify a large cohort of children transfused in the decade prior to second-generation anti-hepatitis C virus HCV donor screening 1982-1992 This will not only identify cases for the study of persistent infection and chronic hepatitis in children but will allow for the determination of the annualized risk of transfusion-associated hepatitis TAH infection in children data that are not currently available
Detailed Description:
BACKGROUND
Accumulating data indicate that 70 to 80 percent of adults infected with the hepatitis C virus HCV develop persistent infection that may be associated with chronic hepatitis cirrhosis hepatocellular carcinoma and end-stage liver disease Despite these potential mortal outcomes the progression is indolent and serious chronic sequelae may not occur for 10 to 50 years by which time many transfused adults have died of unrelated causes Infants and children on the other hand are far more likely to survive their transfusion episode to have a long life span after HCV acquisition and by inference to experience the decades-long evolution to HCV-related cirrhosis and hepatocellular carcinoma
DESIGN NARRATIVE
The years 1982-1992 have been selected because TAH incidence in adults was still high at that time and because all subjects would be under age 15 at enrollment and unlikely to have been exposed to sexual contact or IV drug use Maternal testing is performed to exclude perinatal transmission Sixty-five hundred children who meet the eligibility criteria of the study have been transfused at Childrens National Medical Center CNMC during this period and archival serum specimens are available for 22 percent The total eligible cohort is contacted and asked to provide a blood sample that is tested for antibodies to HCV and to the newly discovered hepatitis G virus HGV Subjects found antibody positive on initial screen are enrolled in long-term followup that includes serial determinations for alanine aminotransferase ALT other liver-related assays viral serology with confirmatory testing PCR for HCV and HGV RNA HCV genotyping and in those with evidence of chronic hepatitis liver biopsy Biopsy may also be performed on a subset with chronic viremia but normal ALT pending approval of an advisory panel of liver experts A serum repository will be established for evaluation of new diagnostic methods for HCV HGV and other etiologic agents of posttransfusion hepatitis
This study will determine the minimal rate of transfusion-induced HCV and HGV infection and will allow for an annualized incidence estimate and a determination of the national burden of transfusion-induced hepatitis virus infection in children a value that is currently unknown In addition by use of archival samples and the interval from transfusion to testing the study will determine the duration of infection and rate of viral persistence Finally prospective followup with liver biopsy will establish the extent of disease in those chronically infected If persistent infection and chronic liver disease are as common in children as in adults this would have major implications for anti-viral therapy programs and might shift treatment emphasis to pediatric populations where response rates might be higher and where long-term benefit would be greater
Accumulating data indicate that 70 to 80 percent of adults infected with the hepatitis C virus HCV develop persistent infection that may be associated with chronic hepatitis cirrhosis hepatocellular carcinoma and end-stage liver disease Despite these potential mortal outcomes the progression is indolent and serious chronic sequelae may not occur for 10 to 50 years by which time many transfused adults have died of unrelated causes Infants and children on the other hand are far more likely to survive their transfusion episode to have a long life span after HCV acquisition and by inference to experience the decades-long evolution to HCV-related cirrhosis and hepatocellular carcinoma
DESIGN NARRATIVE
The years 1982-1992 have been selected because TAH incidence in adults was still high at that time and because all subjects would be under age 15 at enrollment and unlikely to have been exposed to sexual contact or IV drug use Maternal testing is performed to exclude perinatal transmission Sixty-five hundred children who meet the eligibility criteria of the study have been transfused at Childrens National Medical Center CNMC during this period and archival serum specimens are available for 22 percent The total eligible cohort is contacted and asked to provide a blood sample that is tested for antibodies to HCV and to the newly discovered hepatitis G virus HGV Subjects found antibody positive on initial screen are enrolled in long-term followup that includes serial determinations for alanine aminotransferase ALT other liver-related assays viral serology with confirmatory testing PCR for HCV and HGV RNA HCV genotyping and in those with evidence of chronic hepatitis liver biopsy Biopsy may also be performed on a subset with chronic viremia but normal ALT pending approval of an advisory panel of liver experts A serum repository will be established for evaluation of new diagnostic methods for HCV HGV and other etiologic agents of posttransfusion hepatitis
This study will determine the minimal rate of transfusion-induced HCV and HGV infection and will allow for an annualized incidence estimate and a determination of the national burden of transfusion-induced hepatitis virus infection in children a value that is currently unknown In addition by use of archival samples and the interval from transfusion to testing the study will determine the duration of infection and rate of viral persistence Finally prospective followup with liver biopsy will establish the extent of disease in those chronically infected If persistent infection and chronic liver disease are as common in children as in adults this would have major implications for anti-viral therapy programs and might shift treatment emphasis to pediatric populations where response rates might be higher and where long-term benefit would be greater
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01HL056060 | NIH | None | httpsreporternihgovquickSearchR01HL056060 |